Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.90 7.50 8.30 7.90 7.90 7.90 44,043 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.0 -1.5 -0.5 - 30

Eden Research Share Discussion Threads

Showing 9551 to 9572 of 9825 messages
Chat Pages: 393  392  391  390  389  388  387  386  385  384  383  382  Older
DateSubjectAuthorDiscuss
17/9/2020
14:26
Looks like MM made £29.40 by facilitating a roll of 294K shares.Times are, indeed, desperate for everyone.
northwick
17/9/2020
10:11
Corteva Talk Rice..news hTTps://twitter.com/search?q=corteva&;src=recent_search_click
supersonico
17/9/2020
07:25
The fact remains that sales have been pedestrian and no confidence that these are likely to improve Eden having already sold the family silver in order to get some paltry "milestone payments" from distributors just to keep the lights on . Any slight improvement in sales will still be half of SFA as the distributors get the lion's share and insufficent to fund further research. Groundhog day You can imagine how much it costs to get these international patents
hillofwad
17/9/2020
07:03
What is good about the French approval is that it overturns the initial consideration, thus allaying any concerns about the validity and use in France, or elsewhere. Eden is building momentum now and there are still so many regulatory approvals that can land and hopefully will, this side of Christmas. Allowing for immediate sales of Cedroz and then Mevalone for Australia, Eden could start on a real positive note for 2021. It would be good if Eden gave the market confidence and confirmed that initial sales of product had been made to each country as and when so as to bolster investor confidence (which is needed)and demonstrate that regulatory approvals do equal sales. After the initial sales confirmation, everything thereafter would simply update in the interims and annual accounts as normal.
investingisatrickygame
17/9/2020
06:55
Meanwhile back in Kenya the 1st initial product order by Lachlan some years back gathering dust at the back of the warehouse
hillofwad
17/9/2020
06:30
Good news indeed. Office chair on the move. Let’s hope they can generate some sales in the next 5 years.
erinvale
17/9/2020
06:29
Definitely and following on from approval in Spain so recently https://www.hortidaily.com/article/9247894/eden-research-received-approval-for-cedroz-in-spain/
mirandaj
17/9/2020
06:16
France is surely significant.
brucie5
17/9/2020
06:12
New authorisations for CedrozT and Mevalone® hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/new-authorisations-for-cedrozt-and-mevalone-/202009170700032324Z/
supersonico
15/9/2020
17:13
Of the Corteva Kind. 'The patent allows Eden to exploit opportunities of this kind in the Australian market with a patent protected position'. So Eden are saying they are/have/will be using the Corteva model with Corteva or other third parties / ecocidal Behemoths in Australia. So another detailed announcement Of the Corteva Kind is due imo. Also of interest is the 'technology competitive advantage' statement when referring to ecocidal Behemoths 12 hTTps://worldwide.espacenet.com/publicationDetails/inpadocPatentFamily?CC=CN&;NR=107426994A&KC=A&FT=D&ND=6&date=20171201&DB=EPODOC&locale=en_EP
supersonico
15/9/2020
08:04
A shiny new (Australian) office chair. Sales: 2021/22 if we are lucky. At least the share price has ticked up a bit today.
erinvale
15/9/2020
06:54
Key patent granted for Eden's Sustaine technology hTTps://www.investegate.co.uk/eden-research-plc--eden-/rns/key-patent-granted-for-eden-s-sustaine-technology/202009150700049625Y/ Also read post 7722 for more Unmentionable related details So Corteva assesses SustainE in Ukraine,Turkey, EU and Russia and now Eden has a patent that allows them to exploit opportunities of this kind in the Australian market. But they don't tell us with Whom they will be partnering..Is it Sipcam? As usual more Comfort RNS than $$££ RNS detail from Unmentionable.
supersonico
11/9/2020
06:47
A new natural pesticide manages to eliminate pests and pathogens using molecules that 'silence' their genes hTTps://www.agronewscastillayleon.com/un-nuevo-pesticida-natural-logra-eliminar-plagas-y-patogenos-mediante-moleculas-que-silencian-sus The Coop Report photographs the new normal of Italians And among the constants that the Covid has not swept away, the attention paid by Italians to the issues of sustainability re-emerges strongly. While it is true that for 35% of the managers interviewed in the survey "Italy 2021, the Next Normal of Italians" the development of the green economy is one of the trends that will positively characterize the postcovid, this kind of national green conscience translates into related purchases. In the international comparison there is no race. 27% of the inhabitants of the bel country buy more sustainable/eco-friendly products than before the Covid (the French and Spaniards follow spaced with an 18% percentage); 21% - in this case with Spanish customers - increased purchases in stores that promote sustainable products (compared to 17% of Americans and 15% of Germans) and 20% buy more from companies that work with respect for workers. Also worth considering is that 1,700,000 Italians who will experience green purchases for the first time in an emergency ended. hTTp://www.vita.it/it/article/2020/09/10/il-rapporto-coop-fotografa-la-nuova-normalita-degli-italiani/156603/ .......... Valent U.S.A. Opens New Innovation Center in Northern California SAN RAMON, Calif., Aug. 31, 2020– Valent U.S.A. has opened a new state-of-the-art facility in San Ramon, called the North American Innovation Center (NAIC), that physically unites employees from its California technical center in Dublin and headquarters in Walnut Creek. The nearly 100,000 square-foot hub for research and development and headquarter operations for North America is custom-designed to enhance collaboration and innovation. The new site will allow Valent U.S.A. to bring sustainable agriculture solutions and professional products to market with greater speed and effectiveness. hTTps://www.valent.com/Articles/075d883b-284e-48a5-9481-2d344d418376/valent-USA-opens-new-innovation-center
supersonico
10/9/2020
19:37
I am just not convinced. There is just silence and I've seen it before with other companies. They seem to be going through the motions . Investing: you are right about those 3 assumptions. The first point is particularly apparent to me.
chrischas
10/9/2020
17:21
The Right ones seem to think so. I also think the TT announcement could come soon. There are signs of life.
supersonico
10/9/2020
16:39
It seems that water is going up in value. https://www.cnbc.com/quotes/?symbol=9633-HZ&qsearchterm=nongfu Eden is in the right place at the right time. Food supply and water are all necessities for every day life. Will Eden close their first big deal?
investingisatrickygame
10/9/2020
16:20
Chrischas "I am afraid it is a fairytale. Eden does not have any dynamicity to see your dream become reality" I assume you're out of, nearly out of Eden because 1. You don't believe in management 2. Haven't seen product sales of note 3. Don't believe those sales will come So let's say that Mevalone struggles and is a slow build Let's say that Cedroz does okay as soon as all regulatory approvals are through IF Corteva doesn't proceed with Eden and in the absence of any other similar news, you'd expect Eden to plod along as we are now. Fair enough. However, IF Corteva does proceed on the annual indicative numbers as RNS'd, €40 million and we will be told within the next 3 1/2 months, what value do you think that puts on Eden? 380 million shares in issue €40 million annual/ £37 million annual What would be your maths to calculate value? Even if private investors like you and me don't buy on the positive announcement of a deal, Cenkos will be duty bound to update Eden's position and their own interpretation and valuation/target price on Eden. That will inevitably bring in share buys from their audience because 6-7p with £37 million of annual income, pretty much to the bottom line and therefore mostly attributable to the share price, will be a steal and an easy return on investment. I'm interested to see your valuation in the event that this deal crystallises this year, 2020.
investingisatrickygame
10/9/2020
11:31
So we have updates from Unmentionable that don't update. We have short order shown to be similarly competent at investor BS comfort talk while Swedish noir smiles as the right ones buy in on the cheap. 10-Sep-20 10:13:06 6.5999 227,079 Buy* 6.40 6.75 £14.99k
supersonico
10/9/2020
10:24
I am afraid it is a fairytale. Eden does not have any dynamicity to see your dream become reality
chrischas
09/9/2020
15:00
So today there has been over 500,000 in sales. Again, small beer in relation to shares in issue, but in an illiquid stock, damaging to the share price. And a damaged share price erodes confidence and belief and when that happens it triggers more sales, creating a downward spiral. This is why some of the actions suggested above in post 8114 would be so worthwhile for Eden Research Plc, its shareholders and those who might invest. It is also why questions suggested in post 8111 need addressing. If Eden were a brand, it would now have lost its brand value and following. Eden needs to instil faith in its brand. From the messaging we do receive it would appear this is not necessary in its distributor network (Sipcam, Eastman, Corteva maybe) all of whom appear to value Eden's products highly. However, investors, the lifeblood of a Plc don't appear to have faith in Eden. In the absence of some (more than one) blockbuster RNS's that deliver immediate financial impact, Eden has no other recourse to Mcap value save its investor base and potential investor base and it is for this reason that it needs addressing. What isn't working, must be changed where change is possible. For Eden, it is possible? I'd like to know what Cenkos thinks of their client right now and what recommendations, if any, they are making. I'd like to know what Hawthorn thinks of their client right now and what recommendations, if any, they are making. I know I won't get the answer to those, but it would be nice if they were pushing Eden and offering support for change, which ultimately, will make their job of selling and positioning Eden, much easier.
investingisatrickygame
08/9/2020
17:10
Who in their right mind would invest in Eden knowing how poor they are at communicating anything of value and how they have so poorly informed PI's. Unmentionable can't even say Corteva in the Proactive or have the decency to update us on TT which we were told again was due now. So we have updates from Unmentionable that don't update. We have short order shown to be similarly competent at investor BS comfort talk while Swedish noir smiles as the right ones buy in on the cheap. So with that in mind Investing.. your asking way too much from this lot.
supersonico
08/9/2020
16:21
So there has been no trades in Eden for the first two days of this week which suggests to me no urgency to be invested. There is no anticipation around Corteva, no hope, no expectation of Eden landing that deal in the coming months during 2020 (as RNS'd) and if anything, the share price and associated activity doesn't expect Eden to land that deal. Maybe the investment community, those aware and those watching, will wait for a confirmation RNS and chase the price up to reflect that transaction, but this is not a-typical in my experience of how AIM investments work. Surely Eden can deliver some reasonable and realistic communications as to what the Corteva deal means for shareholders if successful and how it would transform the company. When first product sales would occur based on success and what it would mean to the bottom line. This is not hyping the share price, this is informing the market of what a successful deal means for Eden. In the same deliverable they can spell out, for balance, how Eden should be viewed if this deal were not to proceed. The outcome of the above, typically, with the time frame in front of us (less than 4 months) should inject some expectation and enthusiasm into Eden and that wouldn't be unreasonable given the size of the prize. It really is up to Eden to enthuse the market about the Company's prospect in a way that all eyes and ears can understand. And to the contrary, it really is up to Eden NOT to leave investors uneducated in everything Eden so that the Company is so undervalued that it exposes the Company in a number of ways, as well as all of its shareholders. I am still struggling to truly understand Eden's stagnant Market Capitalisation at just £25 million, given all of their IP, product approvals, pending regulatory approvals, Corteval prospects, well advanced insecticide proposition and other stuff of which we are not aware, added to which our corporately successful Chairman has publicly stated during the course of the last 12 months about Eden and where it is going commercially. I'll always advocate that you can't or don't buy what you cannot see and most are not seeing all of this value, largely due to Eden's shortcomings in communicating this message. This view should not be seen as harsh by me as the fully independent barometer that is the share price, is speaking for itself.
investingisatrickygame
Chat Pages: 393  392  391  390  389  388  387  386  385  384  383  382  Older
ADVFN Advertorial
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201126 01:48:33